TG Therapeutics Inc (STU:NKB2)
€ 14.742 -0.034 (-0.23%) Market Cap: 2.35 Bil Enterprise Value: 2.26 Bil PE Ratio: 75.14 PB Ratio: 15.96 GF Score: 72/100

TG Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 10, 2022 / 02:45PM GMT
Release Date Price: €15.34 (-2.29%)
Eric William Joseph
JPMorgan Chase & Co, Research Division - VP & Senior Analyst

Okay. Good morning. Thanks for joining us for the 40th Annual JPMorgan Healthcare Conference. I'm Eric Joseph, Senior Biotech Analyst with the firm. Our next presenting company is TG Therapeutics, and it's my pleasure to welcome CEO, Mike Weiss, to talk to us a little about the company.

There is a Q&A session after the presentation. (Operator Instructions) With that, Mike, thanks for joining us.

Michael S. Weiss
TG Therapeutics, Inc. - Chairman, CEO & President

Thanks, Eric. Really appreciate it. Thanks for having me. I guess you said the 40th Annual. I guess I'm not as old as I thought. I think I'm on my 20-something JPMorgan conference. But really pleased to be here. Hopefully, next year, we'll get to do this live. Finally, I made it off of Wednesday, Thursday and unfortunately, it's virtual, but we'll get there. So thanks again for having us.

Next slide, please. So just on the Slide 2. I will be making some forward-looking statements. So for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot